GoodRx announced a partnership with Pfizer that will launch discounted cash‑price programs for more than 30 essential brand medications on the TrumpRx.gov website. The partnership, announced on February 5, 2026, allows consumers to view and purchase Pfizer drugs at discounts that can reach 85% and average 50% off list price.
GoodRx will serve as the integrated pricing source, pharmacy enablement partner, and consumer‑experience provider for the program. The company is already a core integration partner for a broad slate of manufacturers—including Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Genentech, Gilead Sciences, GlaxoSmithKline, Merck, Novartis, Novo Nordisk, and Sanofi—making this not the first manufacturer integration on TrumpRx but a significant expansion of GoodRx’s pharma‑solutions portfolio.
The partnership aligns with the Trump administration’s Most‑Favored‑Nation pricing policy and positions GoodRx as a key partner for manufacturers seeking to reach uninsured and underinsured patients. “Transparent direct‑to‑consumer prescription pricing helps to ensure millions of Americans have access to the healthcare they deserve,” said Wendy Barnes, President and CEO of GoodRx. “GoodRx gives manufacturers a proven way to launch discounted cash pricing at scale and extend it directly into TrumpRx.”
By integrating with Pfizer on TrumpRx, GoodRx enables the manufacturer to launch discounted programs nationwide, leveraging its nationwide pharmacy network and pricing technology. The move builds on GoodRx’s existing collaborations with Novo Nordisk and Amgen and reflects a broader trend of manufacturers offering direct‑to‑consumer pricing models to improve affordability for patients who self‑pay.
The partnership marks a strategic step for GoodRx, expanding its role as an infrastructure provider for direct‑to‑consumer drug pricing and reinforcing its position in a growing market that seeks to lower prescription drug costs for millions of Americans.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.